Clinical trial of trifunctional antibody in hormonally positive her2 patients
 

not YET RECRUITING, BUT IN THE WORKS:

Fresenius Biotech GmbH, Clinical Development, Frankfurter Ring 193a, 80807 München, Germany
Tel: +49 (0)89/30 65 93 17, e-mail: clinicalstudies@fresenius-biotech.com - 4 -
Metastatic Breast Cancer





Status:
Phase II study on the trifunctional antibody ertumaxomab (anti HER2/neu x anti CD3) in
patients with hormonal receptor positive and HER/2 expressing (1+ and 2+) advanced or
metastatic breast cancer.

phase II

Her2/neu positive metastatic breast cancer patients not qualifying for treatment with
Herceptin and failing anti-hormonal therapies

ertumaxomab (anti Her2 x anti CD3)

Fresenius Biotech GmbH
Tel: +49-(0)89-306 593-17
Email: clinicalstudies@fresenius-biotech.com

Not yet recruiting


The clinical trials are conducted in collaboration with TRION Pharma.

LOOK UP FRESENIUS BIOTECH IN GOOGLE TO SEARCH FOR WEBSITE

HOPE THIS HELPS!
Lani